Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by MyKnighton Jan 17, 2020 11:22am

52 Views

Post# 30565188

RE:RE:RE:RE:RE:RE:RE:RE:RE:BASHER ACCOUNTS : DEBBIECHANDLER , SCOTTY

Just look at GW pharma as an example revenus:
https://www.globenewswire.com/news-release/2019/11/05/1941593/0/en/GW-Pharmaceuticals-plc-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-Ended-September-30-2019.html

Their market is epidolex, and their revenues are 296 Millions/2019 --- MC of 5 Billions
Before this GW pharma wasn't making money...

Now GVHD revenue alone is the double of that...

the market will determine the price of Kaly...

But I remember when I was talking to Rob this summer he mention that we should be at LEAST the same price then GW pharma.... at the time I tough that he was agressive...
But after the incredible result that we had, I can see what he was looking at...

Do your DD, we will now pretty sooonnnnnn....

RE:RE:RE:RE:RE:RE:RE:RE:BASHER ACCOUNTS : DEBBIECHANDLER , SCOTTY

Here's a few reason:

World Monopoly for GVHD.

Market of 650 Millions/Year for Pre-GVHD(for the 6 big country only/min)

This mean over a Billions a year for the full planet.

Market For Post(GVHD) not evaluated yet... would be Billions a year.

People with GVHD symptom can leave over 20 years ...

Patent already setup for the planet.

Revenue out of Licences/Royalties, no big building to maintain and all cost that goes around this. Plain cash

Licence in Europe this Year, no need to wait for FDA Approval.

FDA Fast track and orphean drug for kaly.

Just to name a few...
That's for GVHD only. They have a product call Kal-1816 that will compete on the opiod market(new ball game 50 Billions/year)... this will be on the few years to come. they also have other prodcut do your DD.

Now knowing that this business would bring you around a Billions a year, and would grab the full GVHD market. If you we're the CEO of a big pharma already dealing in the GVHD sector what would you do?

Let Kaly take the monopole and loose all revenu from GVHD

Licence at the beginning, once happy with the result buy them

I know what I would do, especially that 5 Billions for them is nothing for this market.

RE:RE:RE:RE:RE:RE:RE:BASHER ACCOUNTS : DEBBIECHANDLER , SCOTTY

Thanks for the respons MyKnight. I understand potential for sure, but why the figure of 2-5 b? I haven't run across anything myself to draw that conclusion. Can you share something I missed?